Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1994 Jul;49(7):649–651. doi: 10.1136/thx.49.7.649

Effect of an oral gold compound, auranofin, on non-specific bronchial hyperresponsiveness in mild asthma.

M Honma 1, G Tamura 1, K Shirato 1, T Takishima 1
PMCID: PMC475050  PMID: 8066558

Abstract

BACKGROUND--A recent double blind clinical trial in Japan has shown that auranofin (6 mg/day) is a useful treatment for patients with moderate to severe asthma. To investigate the mechanism of action of auranofin the bronchial responsiveness to inhaled methacholine has been studied in well controlled asthmatic subjects. METHODS--Nineteen adult asymptomatic asthmatic subjects received auranofin (3 mg orally twice a day) or inactive placebo in random order for 12 weeks in a double blind fashion. Bronchial responsiveness to inhaled methacholine and pulmonary function tests were measured at the same time on different days before, and six and 12 weeks after, each treatment. RESULTS--Non-specific bronchial hyperresponsiveness 12 weeks after treatment with auranofin was decreased compared with that before treatment with auranofin and 12 weeks after treatment with inactive placebo, although the treatment did not improve pulmonary function tests. CONCLUSIONS--Non-specific bronchial hyperresponsiveness 12 weeks after treatment with auranofin is decreased in a group of mild asymptomatic asthmatic patients with normal lung function.

Full text

PDF
649

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arm J. P., Spur B. W., Lee T. H. The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. J Allergy Clin Immunol. 1988 Oct;82(4):654–660. doi: 10.1016/0091-6749(88)90979-7. [DOI] [PubMed] [Google Scholar]
  2. Bernstein D. I., Bernstein I. L., Bodenheimer S. S., Pietrusko R. G. An open study of auranofin in the treatment of steroid-dependent asthma. J Allergy Clin Immunol. 1988 Jan;81(1):6–16. doi: 10.1016/0091-6749(88)90213-8. [DOI] [PubMed] [Google Scholar]
  3. Brooks S. M., Bernstein I. L., Raghuprasad P. K., Maccia C. A., Mieczkowski L. Assessment of airway hyperresponsiveness in chronic stable asthma. J Allergy Clin Immunol. 1990 Jan;85(1 Pt 1):17–26. doi: 10.1016/0091-6749(90)90216-q. [DOI] [PubMed] [Google Scholar]
  4. Cockcroft D. W., Ruffin R. E., Dolovich J., Hargreave F. E. Allergen-induced increase in non-allergic bronchial reactivity. Clin Allergy. 1977 Nov;7(6):503–513. doi: 10.1111/j.1365-2222.1977.tb01481.x. [DOI] [PubMed] [Google Scholar]
  5. Cuss F. M., Dixon C. M., Barnes P. J. Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet. 1986 Jul 26;2(8500):189–192. doi: 10.1016/s0140-6736(86)92489-x. [DOI] [PubMed] [Google Scholar]
  6. Golden J. A., Nadel J. A., Boushey H. A. Bronchial hyperirritability in healthy subjects after exposure to ozone. Am Rev Respir Dis. 1978 Aug;118(2):287–294. doi: 10.1164/arrd.1978.118.2.287. [DOI] [PubMed] [Google Scholar]
  7. Gordon T., Sheppard D., McDonald D. M., Distefano S., Scypinski L. Airway hyperresponsiveness and inflammation induced by toluene diisocyanate in guinea pigs. Am Rev Respir Dis. 1985 Nov;132(5):1106–1112. doi: 10.1164/arrd.1985.132.5.1106. [DOI] [PubMed] [Google Scholar]
  8. Irvin C. G., Berend N., Henson P. M. Airways hyperreactivity and inflammation produced by aerosolization of human C5A des arg. Am Rev Respir Dis. 1986 Oct;134(4):777–783. doi: 10.1164/arrd.1986.134.4.777. [DOI] [PubMed] [Google Scholar]
  9. Katsumata U., Miura M., Ichinose M., Kimura K., Takahashi T., Inoue H., Takishima T. Oxygen radicals produce airway constriction and hyperresponsiveness in anesthetized cats. Am Rev Respir Dis. 1990 May;141(5 Pt 1):1158–1161. doi: 10.1164/ajrccm/141.5_Pt_1.1158. [DOI] [PubMed] [Google Scholar]
  10. Kraan J., Koëter G. H., van der Mark T. W., Boorsma M., Kukler J., Sluiter H. J., De Vries K. Dosage and time effects of inhaled budesonide on bronchial hyperreactivity. Am Rev Respir Dis. 1988 Jan;137(1):44–48. doi: 10.1164/ajrccm/137.1.44. [DOI] [PubMed] [Google Scholar]
  11. Marone G., Columbo M., Galeone D., Guidi G., Kagey-Sobotka A., Lichtenstein L. M. Modulation of the release of histamine and arachidonic acid metabolites from human basophils and mast cells by auranofin. Agents Actions. 1986 Apr;18(1-2):100–102. doi: 10.1007/BF01987994. [DOI] [PubMed] [Google Scholar]
  12. Marone G., Columbo M., Galeone D., Guidi G., Kagey-Sobotka A., Lichtenstein L. M. Modulation of the release of histamine and arachidonic acid metabolites from human basophils and mast cells by auranofin. Agents Actions. 1986 Apr;18(1-2):100–102. doi: 10.1007/BF01987994. [DOI] [PubMed] [Google Scholar]
  13. Muranaka M., Nakajima K., Suzuki S. Bronchial responsiveness to acetylcholine in patients with bronchial asthma after long-term treatment with gold salt. J Allergy Clin Immunol. 1981 May;67(5):350–356. doi: 10.1016/0091-6749(81)90079-8. [DOI] [PubMed] [Google Scholar]
  14. Parente J. E., Wong K., Davis P., Burka J. F., Percy J. S. Effects of gold compounds on leukotriene B4, leukotriene C4 and prostaglandin E2 production by polymorphonuclear leukocytes. J Rheumatol. 1986 Feb;13(1):47–51. [PubMed] [Google Scholar]
  15. Ryan G., Latimer K. M., Dolovich J., Hargreave F. E. Bronchial responsiveness to histamine: relationship to diurnal variation of peak flow rate, improvement after bronchodilator, and airway calibre. Thorax. 1982 Jun;37(6):423–429. doi: 10.1136/thx.37.6.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ryan G., Latimer K. M., Juniper E. F., Roberts R. S., Hargreave F. E. Effect of beclomethasone dipropionate on bronchial responsiveness to histamine in controlled nonsteroid-dependent asthma. J Allergy Clin Immunol. 1985 Jan;75(1 Pt 1):25–30. doi: 10.1016/0091-6749(85)90007-7. [DOI] [PubMed] [Google Scholar]
  17. Scheinberg M. A., Santos L. M., Finkelstein A. E. The effect of auranofin and sodium aurothiomalate on peripheral blood monocytes. J Rheumatol. 1982 May-Jun;9(3):366–369. [PubMed] [Google Scholar]
  18. Smith P. R., Brown G. M., Meyers O. L. An open comparative study of auranofin vs. gold sodium thiomalate. J Rheumatol Suppl. 1982 Jul-Aug;8:190–196. [PubMed] [Google Scholar]
  19. Sutton B. M., McGusty E., Walz D. T., DiMartino M. J. Oral gold. Antiarthritic properties of alkylphosphinegold coordination complexes. J Med Chem. 1972 Nov;15(11):1095–1098. doi: 10.1021/jm00281a001. [DOI] [PubMed] [Google Scholar]
  20. Takaishi T., Morita Y., Kudo K., Miyamoto T. Auranofin, an oral chrysotherapeutic agent, inhibits histamine release from human basophils. J Allergy Clin Immunol. 1984 Sep;74(3 Pt 1):296–301. doi: 10.1016/0091-6749(84)90261-6. [DOI] [PubMed] [Google Scholar]
  21. Takishima T., Hida W., Sasaki H., Suzuki S., Sasaki T. Direct-writing recorder of the dose-response curves of the airway to methacholine. Clinical application. Chest. 1981 Nov;80(5):600–606. doi: 10.1378/chest.80.5.600. [DOI] [PubMed] [Google Scholar]
  22. Walz D. T., DiMartino M. J., Griswold D. E., Intoccia A. P., Flanagan T. L. Biologic actions and pharmacokinetic studies of auranofin. Am J Med. 1983 Dec 30;75(6A):90–108. doi: 10.1016/0002-9343(83)90481-3. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES